# Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

> **NCT01255709** · PHASE2 · COMPLETED · sponsor: **Amphastar Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Arm T1: Primatene Mist HFA
- **DRUG:** Arm T2: Primatene Mist HFA
- **DRUG:** Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)

## Key facts

- **NCT ID:** NCT01255709
- **Lead sponsor:** Amphastar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01255709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01255709, "Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01255709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*